Beauty M&A holds at 31 deals in 2026 while consumer M&A falls 12%

Beauty notched 31 private equity and strategic transactions in 2026, holding roughly flat against last year even as broader consumer M&A contracted 12% year-over-year. That is the headline finding of the 'US Private Equity Mid-Market Monitor' from international investment bank DC Advisory, and it says something precise about where buyers think defensible value sits.

The gap matters. A subsector that keeps its deal count stable while the surrounding category shrinks by double digits is attracting capital for reasons that do not depend on the wider cycle. According to DC Advisory, those reasons are brand loyalty and positioning on emerging consumer trends, with GLP-1 adoption at the top of the list.

What is driving the premium?

Skin care remains the most active beauty subsector in the data. Buyers increasingly favour science-backed products focused on skin health and longevity, the report found — a formulation story as much as a finance story.

The GLP-1 effect is the most concrete demand signal in the report. DC Advisory estimates GLP-1 adoption at 8% to 10% of the US population. Rapid weight loss at that scale creates downstream demand: elasticity- and collagen-focused skin care, plus hair care addressing regrowth and density.

For formulators, that demand profile maps onto specific claims work:

• Collagen support and elasticity claims for skin losing firmness after significant weight change
• Hair density and regrowth positioning, which pulls products toward ingredient stories on scalp and follicle health
• Clinical substantiation, because 'science-backed' is the qualifier buyers are paying for

The takeaway: the acquisition premium is landing on brands that can evidence function, not on those that trade on fragrance or packaging alone.

Who is buying?

Asian strategic buyers are becoming an increasingly important source of capital, according to the report, as they expand into US and European prestige beauty assets. That continues a pattern trade watchers will recognise: strategics from Asia using M&A to buy entry into Western prestige distribution rather than building it.

For founders and mid-market owners, a broader buyer pool changes the negotiation. More bidders from Asia means more optionality on exit, and prestige assets with a skin-health narrative are the ones screening best.

Why has beauty stayed resilient?

Luc-Henry Rousselle, Managing Director at DC Advisory, framed the category's performance in plain terms. 'Beauty and personal care has been a more resilient and steady category over the long run,' he told Cosmetics Business.

The mechanism is straightforward. Loyal repeat purchasers smooth revenue, science-backed positioning supports pricing power, and new demand pools — here, GLP-1 users — refresh the growth story without requiring new categories. Stability plus a fresh demand narrative is exactly the combination mid-market investors screen for.

For procurement and development teams, the read-across is practical. Expect continued acquirer interest in suppliers and brands with clinical data assets, patents, or published studies attached to their ingredient stories. Expect GLP-1-adjacent claims — elasticity, collagen, density, regrowth — to keep multiplying on shelf, since capital is now explicitly validating them.

The next data point to watch is whether the 31-deal pace holds into the second half of 2026, and whether DC Advisory's next mid-market monitor shows Asian strategic buyers moving from minority stakes toward controlling positions in European prestige.